Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q3 FY21 results · Oct–Dec 2020
Solara Active Pharma Sciences reported revenue from operations of ₹426.69 crore (up 24.2% from Q3 FY20) and net profit of ₹65.78 crore (up 59.2% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a consolidated basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 426.69 | 343.68 | +24.2% | 397.56 | +7.3% |
| Other income | 8.29 | 6.08 | +36.3% | 6.12 | +35.5% |
| Total income | 434.98 | 349.76 | +24.4% | 403.68 | +7.8% |
| Profit before tax | 65.79 | 41.33 | +59.2% | 56.77 | +15.9% |
| Net profit for the period | 65.78 | 41.33 | +59.2% | 56.69 | +16.0% |
| EPS, basic (₹) | 18.47 | 16.00 | not comparable | 19.21 | −3.9% |
| Net margin (%) | 15.4 | 12.0 | 14.3 |
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 426.69 | 343.68 | +24.2% | 397.56 | +7.3% |
| Other income | 8.29 | 6.10 | +35.9% | 5.68 | +46.0% |
| Total income | 434.98 | 349.78 | +24.4% | 403.24 | +7.9% |
| Profit before tax | 65.78 | 41.21 | +59.6% | 55.94 | +17.6% |
| Net profit for the period | 65.78 | 41.21 | +59.6% | 55.94 | +17.6% |
| EPS, basic (₹) | 18.48 | 15.95 | not comparable | 18.97 | −2.6% |
| Net margin (%) | 15.4 | 12.0 | 14.1 |
Consolidated
- Filed with BSE
- 04 Feb 2021, 11:45 IST
- Board meeting
- 03 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 04 Feb 2021, 11:45 IST
- Board meeting
- 03 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE